Physician profile
David D Hess
NPI 1942204425
$5,013.87
in general payments reported to CMS, 2019-2025
32 companies · $639 in 2025
The $639 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $471 · 2021: $880 · 2022: $787 · 2023: $661 · 2024: $453 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,784.25 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $812.49 | 2019-2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $612.69 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $275.82 | 2019-2025 | Stelara, Tremfya, Simponi |
| Ironwood Pharmaceuticals, INC | $236.44 | 2019-2024 | Linzess |
| Erbe USA INC | $200.00 | 2023 | Erbe Vio3 |
| Ferring Pharmaceuticals INC. | $174.78 | 2019-2023 | Rebyota |
| Gilead Sciences, INC. | $171.49 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $107.11 | 2019-2024 | Dificid |
| Olympus America INC. | $76.86 | 2025 | Olympus, Single Use Repositionable Clip, Single Use Electrosurgical Snare Sd-400 |
| Pfizer INC. | $66.69 | 2019 | |
| Nestle Healthcare Nutrition INC. | $58.53 | 2021-2023 | |
| Sanara Medtech INC. | $47.76 | 2025 | Celleraterx |
| Celgene Corporation | $39.62 | 2021-2022 | |
| Novo Nordisk INC | $37.44 | 2025 | Wegovy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $33.97 | 2024-2025 | Voquezna |
| Concordia Pharmaceuticals INC. | $29.98 | 2019 | |
| Genzyme Corporation | $28.83 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $27.71 | 2024-2025 | Dupixent |
| Qol Medical, LLC | $26.35 | 2025 | Sucraid |
| Allergan, INC. | $25.88 | 2020 | |
| Ucb, INC. | $17.93 | 2019 | |
| Braintree Laboratories, INC. | $15.98 | 2022 | |
| Ardelyx, INC. | $15.20 | 2024 | Ibsrela |
| Madrigal Pharmaceuticals | $14.54 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $13.33 | 2024 | |
| Axonics, INC. | $12.71 | 2021 | |
| Evoke Pharma, INC. | $12.59 | 2021 | |
| Redhill Biopharma INC. | $12.54 | 2021 | |
| Daiichi Sankyo INC. | $11.27 | 2019 | |
| Romark Laboratories, Lc | $7.23 | 2019 | |
| Organon LLC | $5.86 | 2025 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.